Arcus Biosciences, Inc.
RCUS
NYSE·Healthcare·Biotechnology·Mkt cap $3.7B
$29.66
▼ -1.56%
P/E
-7.55
Mkt Cap
$3.7B
52-Wk Range
$11.04–$31.74
52-Week Range
$11.04 - $31.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 159.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Dual-mechanism approach combining checkpoint inhibition with metabolic pathway targeting for enhanced anti-tumor immunity
- Strategic partnerships with AstraZeneca and other leading pharmaceutical companies providing development resources and market access
- Proprietary small-molecule and monoclonal antibody platform technology enabling multiple therapeutic modalities
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Advancement of Domvanalimab Phase 3 trial in combination with Imfinzi for unresectable Stage III NSCLC
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+27.2% over 3m
Quality
Excellent
Emerging growth company (-55% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying RCUS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
AUG 5, 2026
Reported EPS of -$0.72 vs -$0.89 consensus (+19.2% surprise). Revenue of $41.0M vs $22.0M expected (+86.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+19.2%
Revenue trend · last 8Q
—
-16%
-81%
+310%
-46%
+27%
-39%
-74%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$48.0M
$26.0M
$28.0M
$160.0M
$26.0M
$33.0M
$17.0M
$41.0M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-221.9%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Aug 7, 2026
vs Industry
How RCUS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related